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Papillomaviruses occasionally cause severe, non-regressing or recurrent infections in their human and 
animal hosts. The mechanisms underlying these atypical infections are not known. Canine oral 
papillomavirus (COPV) typically regresses spontaneously and is an important model of mucosal human 
papillomavirus infections. A severe, naturally-occurring, non-regressing, COPV infection provided an 
opportunity to investigate some aspects of viral pathogenicity and host immunity. In this case, the 
papillomas proved refractory to surgical and medical treatments, including autogenous vaccination and 
vaccination with capsid (L1) virus-like particles. High levels of induced anti-L1 antibodies appeared to 
have no effect on the infection. The papillomas spread to oesophageal mucosa, peri-oral haired skin, 
and remote cutaneous sites. Isolation of COPV from the animal and sequencing of several regions of 
the viral genome showed no differences to the COPV prototype. Experimental infection of beagle dogs 
with this viral isolate resulted in the uncomplicated development and regression of oral warts within the 
usual period, indicating that the virus was not an unusual pathogenic variant. These findings support the 
hypothesis that the recurrent lesions seen in some human papillomavirus infections, such as recurrent  
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laryngeal papillomatosis, are associated with specific defects in host immunity rather than variations in 
viral pathogenicity. 
 
Key words: HPV, COPV, VLP, vaccine, immunity, recurrent papillomatosis 
 
INTRODUCTION 
The papillomaviruses are a ubiquitous group of pathogens infecting the skin and internal squamous 
mucosae of most vertebrate species, including man. These are classified by genotype and, to date, more 
than 80 types of human papillomavirus (HPV) have been isolated and sequenced (Delius et al., 1998), 
with more than 130 types identified by detection of capsid (L1) encoding DNA (de Villers, 1997). The 
viruses are associated with a spectrum of epithelial atypia ranging from benign epithelial proliferations 
(warts) to cancer. Different viral types induce warts on skin, oro- and nasopharynx, larynx and 
anogenital tissue. The types infecting the anogenital tract have received considerable attention. 
Anogenital warts, induced mainly by HPV-6 and 11, are the commonest viral sexually-transmitted 
disease in the U. K. (Howett et al., 1997). The erratic natural history of these lesions represents a 
significant therapeutic challenge. Infection with a subset of genital HPV types is strongly associated 
with the subsequent development of carcinoma of the uterine cervix and other anogenital malignancies 
in women, to the extent that HPV-16 and 18 have been defined as human carcinogens (Anon., 1996) 
with over 90% (Bosch et al, 1995) and maybe all (Walboomers and Meijer, 1997) cervical carcinoma 
tissues positive for HPV DNA. Papillomavirus infections therefore do not result in trivial, albeit 
unsightly sequelae, but are associated with life-threatening diseases. The development of strategies for 
the prevention or treatment of these infections is a high priority. 
 
The development of such strategies requires an understanding of the host response to infection, which 
must encompass both innate and acquired immune defences. Papillomavirus infections result in lesions 
which persist for a variable period ranging from weeks to months or years. The infectious cycle of the 
virus is one in which viral replication, high level expression of viral proteins and viral assembly occur 
in terminally-differentiating epithelial cells remote from systemic immune defences and destined for 
death by apoptotic or similar mechanisms. The production of infectious virus is not accompanied by 
inflammation, and the activation of host defences is late. The importance of host immunity in the  
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control of papillomavirus infections is demonstrated in individuals immunocompromised either as a 
consequence of other diseases such as HIV or by therapeutic immunosuppression after organ 
transplantation (Palefsky et al., 1998). These people exhibit persistent and florid HPV-induced lesions, 
refractory to therapy. However, even in immunocompetent individuals there is a spectrum of responses 
to infection, ranging from clearance of virus with no clinical disease through to persistent lesions 
refractory to all treatment modalities (Beutner and Ferenczy, 1997). This latter scenario is seen 
dramatically in individuals with recurrent respiratory papillomatosis (RRP). The general view is that 
individuals with persistent and recurrent florid infections of the type seen in RRP have an underlying 
and specific inability to mount a response to certain HPV types. However, it is possible that such 
infections are the consequence of infection with viral variants with an enhanced pathogenicity including 
immune evasion mechanisms.  
 
Testing these hypotheses in humans is beset with ethical and logistic difficulties but natural 
papillomavirus infections in animals could illuminate these issues. Canine oral papillomavirus (COPV) 
infection is a valuable model for the analysis of many aspects of papillomavirus pathogenesis. 
COPV induces florid warts on the oral mucosa in domestic dogs and wild canids (for review see 
Nicholls and Stanley, 1999). Typically, COPV infection has an incubation period of 4-8 weeks 
followed by spontaneous immune-mediated regression within a further 4-8 weeks (Chambers and 
Evans, 1959). Persistence or neoplastic progression of COPV-induced papillomas has rarely been 
reported. In this report, we describe a case of naturally-occurring COPV infection in which the 
papillomas failed to regress and were refractory to all treatments, including vaccination. High levels of 
anti-L1 antibody were present throughout the period of investigation and after vaccination with L1 
virus-like particles (VLPs) and an autogenous vaccine. Isolation of COPV from the animal and 
sequencing of several regions of the viral genome showed no differences to the COPV prototype. 
Experimental infection of beagle dogs with this viral isolate resulted in the uncomplicated development 
and regression of oral warts within the usual period, indicating that the virus was not an unusual 
pathogenic variant. 
 
MATERIALS AND METHODS 
Immunohistochemistry   
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Paraffin sections of formalin-fixed tissue were cut onto Vectabond coated slides (Vector Laboratories), 
dewaxed (3 x 5 min.) in xylene (BDH) and rehydrated through ethanol (BDH) dilutions (100%, 100% 
95%, 70%, 30%, 3 min. each). After two 3-minute washes in PBS (phosphate buffered saline, Dept. of 
Pathology, University of Cambridge), endogenous peroxide was quenched for 30 min. in 0.3% 
hydrogen peroxide (Fisons) in PBS. After washing in PBS (3 x 3 min.), sections were incubated in 
normal goat serum (20% in PBS) for 30 min. at room temperature. The goat serum was blotted off and 
the primary antibody (CAMVIR-1 mouse IgG2a monoclonal, Dept. of Pathology, University of 
Cambridge. diluted 1:1000 in PBS) was applied overnight at 4 °C in a humid box. After washing as 
above, the secondary antibody (biotinylated polyclonal goat anti-mouse IgG2a, Amersham, 1:400 in 
PBS) was applied for 30 min. Slides were washed then incubated for 30 min. in peroxidase-conjugated 
avidin-biotin complex (Vectastain Elite, Vector Laboratories). Following washing, the chromogenic 
solution (0.06% 3,3' diaminobenzidine tetrahydrochloride, 0.01% hydrogen peroxide in 0.1M Tris 
(BDH) pH 7.5) was applied and the reaction monitored by microscopy until completion. After washing, 
the sections were counterstained (Carazzi's haematoxylin, 45 seconds), dehydrated through graded 
alcohols and mounted in di-butyl-polystyrene-xylene (DPX, BDH). Positive control sections were 
canine oral papillomas with virions confirmed by transmission electron microscopy. Negative control 
sections were from normal canine oral mucosa. 
 
DNA in situ hybridisation 
Sections on Vectabond-coated slides (Vector Laboratories) were dewaxed and rehydrated as above and 
washed in PBS (2 x 3 min.). After protease K digestion in a humidified box (50 µg/ml in 0.02M Tris 
pH 7.4, 2mM CaCl2 for 15 min. at 37 °C), sections were washed in PBS (2 x 5 min.), dehydrated 
through graded alcohols (30 s each) and air-dried. The section was covered in a digoxigenin-labelled, 
nick-translated (Boehringer-Ingelheim) genomic COPV DNA probe diluted 1:25 in hybridisation buffer 
(2 x SSC, 5% dextran sulphate, 0.2% Marvel (Premier Beverages), 50% deionised formamide), 
coverslipped and sealed with cow gum (Cow Proofings Ltd.). After denaturation on a hot plate (6 min. 
at 95 °C), slides were quenched in an ice bath then incubated overnight at 37 °C.  
 
The gum was removed with forceps and the coverslips soaked off in 2 x SSC, 0.1% SDS. Slides were 
washed at room temperature in 0.5 x SSC (3 x 5 min.) at 55 °C in 50% formamide/1 x SSC for 10 min.,  
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and at 55 °C in 0.5 x SSC (3 x 5 min.). After 30 min. in 0.5% blocking buffer (Boehringer-Ingelheim), 
the sections were rinsed briefly in buffer 1 (0.1M Tris pH 7.5, 0.1M NaCl, 2mM MgCl2, 0.05% Triton-
X 100) and covered with 100 µl alkaline-phophatase conjugated anti-digoxigenin Fab fragments 
(Boehringer-Mannheim) 1:5000 in buffer 1 for 1 hour in a humid box. The slides were washed in buffer 
1 (3 x 5 min.), equilibrated for 5 min. in buffer 3 (0.1M Tris pH 9.5, 0.1M NaCl, 50mM MgCl2) then 
covered with 100 µl of 0.18 mg/ml 5-bromo-4-chloro-3-indolyl phosphate (Boehringer-Mannheim), 
0.34 mg/ml nitroblue tetrazolium chloride (Boehringer-Mannheim) in buffer 3 and developed in the 
dark overnight. The reaction was stopped in TE buffer for 10 min. and the sections counterstained, 
washed in distilled water (2 x 5 min.) and mounted in Aquamount (Gurr).  
 
Electron microscopy 
Tissue cubes (1 mm) were dewaxed by three changes of xylene over 2 hours. After 15 min. in 100% 
ethanol, the samples were placed in 2% osmium tetroxide for 1 hour before being dehydrated via 
graded ethanols (40%, 70%, and 90%, for 10 min. each, followed by 100% for 3 x 15 min.). After 
submersion in propylene oxide (2 x 15 min.) the samples were placed overnight in a 1:1 mixture of 
propylene oxide and embedding resin (68% (v/v) dodecyl succinic anhydride, 32% (v/v) methyl nadic 
anhydride, 4% (v/v) dimethylaminomethyl phenol). The following morning the samples were placed 
into resin for 6 hours before embedding and baking overnight. Sections were examined under a Hitachi 
H-100 electron microscope. 
 
ELISA 
Flexible PVC microplates were coated with 100 ng per well of purified COPV particles suspended in 
carbonate buffer, pH 9.6, at 4 °C overnight. The plates were washed with PBS/0.05% Tween 20 and 
blotted dry prior to the addition of 100 µl per well of PBS/Tween containing 2% w/v skimmed milk 
powder (ELISA diluent) and incubation at 37 °C for 30 min.. Following further washing, 50 µl aliquots 
of individual serum dilutions, from a doubling series made for each dog serum sample, were added to 
duplicate wells of the coated plates. Negative controls received diluent alone. The plates were re-
incubated at 37°C for 1.5 hours, washed again, and peroxidase-conjugated, rabbit anti-dog IgG (1/500, 
ICN immunobiologicals) was added to all wells. Following incubation for a further 1.5 hours and a final 
wash, the plates were developed using an s-phenylene diamine/peroxide substrate in urea buffer  
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(Sigmafast). Colour development was stopped with 20% sulphuric acid and absorbance levels were 
read at 490 nm using a Molecular Devices plate reader. The titre was expressed as the reciprocal of the 
dilution producing 50% of the maximum absorbance. 
 
Viral isolation 
Fresh frozen papillomas were diced finely and added to 15 ml PBS before Dounce homogenisation 
(Jencons). Both supernatant and debris were saved and processed separately.  
The supernatant was poured off and centrifuged for 20 min. in a Sorval SS34 rotor at 7,500 rpm to 
pellet the nuclei. The pellet was resuspended in 4 ml of PBS and sonicated (Soniprep 150, MSE) on ice 
for 1 minute at power level 22. The lysate was layered onto 0.75 ml sucrose and centrifuged in an 
SW55Ti rotor at 34,000 rpm for 2 hours at 18 °C. The pellet was resuspended in 2 ml PBS before 
further sonication on ice for 10 seconds. Caesium chloride solution (1.92 g in 3 ml PBS, refractive 
index 1.381) was added and mixed by inversion. The refractive index was confirmed (Refractometer 
Model 60/ED, Bellingham and Stanley) as 1.365 (1.33 g/cm
3) before centrifugation in an SW55 Ti 
rotor at 34,000 rpm for 18 hours at 18 °C. The viral band was extracted and sealed in dialysis tubing 
(Medicell) and dialysed against PBS for four hours. 
 
Viral challenge 
Tenfold serial dilutions of the purified COPV isolate in a volume of 50 µl were injected superficially 
with a 25 g needle into the mucosa of the upper lip of beagles under general anaesthesia. The resulting 
vesicle or bleb was then punctured superficially 10 times with the same needle. Control sites received 
PBS instead of viral solution. 
 
Viral PCR and sequencing 
Primer pairs to regions within each of the viral open reading frames were designed and synthesised. To 
each 0.5 ml eppendorf tube was added 72 µl of distilled water, 2 µl dNTPs (10mM each of dATP, 
dGTP, dCTP, dTTP - Pharmacia), 5 µl of 5 µM Primer 1, 5 µl of 5 µM Primer 2, 5 µl (approx. 20 ng) 
of COPV DNA (extracted from fresh warts of the affected dog), 10 µl of 10x Taq buffer and 1 µl of 
Taq polymerase (both from Enzyme Technologies). In order to run all reactions together, a stepped 
annealing temperature was built into the cycle. Using a GeneAmp 9600 thermal cycler (Perkin-Elmer) a  
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5 min. 94 °C step was followed by 30 cycles of 94 °C, 53.4 °C, 57.1 °C, 58.1 °C, 63.6 °C, and 72.0 °C 
for 1 min. each, with a final annealing step of 72 °C for 5 min. before cooling to 4 °C. The products 
were analysed by 1% agarose gel electrophoresis alongside a 100 bp DNA ladder (Gibco). 
 
RESULTS 
A 3.5 year old neutered female labrador with severe oral papillomatosis (Fig. 1) was presented to one of 
the authors (BK). Diagnosis was established by histology of formalin-fixed paraffin-embedded tissue, 
immunohistochemical detection of the L1 viral capsid protein, in situ detection of COPV DNA (Fig. 2), 
and electron microscopic detection of viral particles (Fig. 3). 
 
Removal of initial warts by electrocautery was followed in three weeks by appearance of a more 
abundant recurrent crop. Over the next eight months, further attempts at resolving the disease included 
electrocautery, surgical crushing of warts (to stimulate immunity), oral interferon-alpha, oral 
levamisole, intravenous immunoregulin, intravenous vincristine, subcutaneous vaccination with COPV 
L1-VLPs (five doses) and subcutaneous vaccination with an autogenous vaccine derived from 
homogenised warts (see Table 1). No significant response was seen and the dog was euthanased. Post-
mortem examination revealed papillomas thoughout the oral cavity and extending down the oesophagus 
(Fig. 4). Papillomas were seen on the haired skin of the face, as well as more remote cutaneous sites 
such as the pinna and forelimbs. Examination of material removed post-mortem confirmed the presence 
of COPV in the lesions from oesophagus (Fig. 5), haired skin, and oral cavity. These data add 
oesophageal mucosa to the tissues known to be affected by COPV. Interestingly, a papilloma developed 
on peri-vulval skin but a biopsy was not available for confirmation of viral involvement. 
 
No significant lymphocyte infiltrate was seen in biopsies of the papillomas. This is in contrast to the 
findings in warts regressing after experimental infection, in which numerous infiltrating CD4
+ and CD8
+ 
cells are present (manuscript in preparation). There was no haematological evidence of 
immunosuppression. The total white cell count was 7800/µl, at the low end of the normal range (8-
18,000/µl). The neutrophil count was 5900/µl (normal range, 3-12,000/µl) and the lymphocyte count 
was 1900/µl (normal range, 1000-4800/µl). Serum protein electrophoresis revealed increased gamma 
globulins (1.28 g/dl, normal range of 0.4-1.0). Unfortunately, logistical factors prevented the  
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undertaking of lymphocyte functional assays, since the affected dog (USA) and the authors’ laboratories 
(UK) were widely separated. No siblings of the affected dog were traceable, so a possible familial 
predisposition to florid papillomatosis could not be assessed.  
To determine whether the severe clinical signs were due to an unusually pathogenic strain of COPV, the 
virus was isolated and injected into beagles. The lesions appeared and regressed normally. PCR 
amplification and sequencing of several regions of the isolated viral DNA (Table 2), including the 
entire L1 open reading frame, showed no differences from the COPV prototype sequence determined 
by Delius and others (1994). Additionally, positive immunohistochemistry findings (data not shown) 
with a COPV E4 antibody, raised against E4 derived from the prototype COPV sequence, further 
confirms the identity of this viral isolate, since E4 is highly divergent between papillomaviruses. 
Serum samples were collected weekly during the period of vaccination with COPV L1 VLPs and 
autogenous vaccine. Sera were analysed by ELISA, using purified COPV virions as the antigen (Fig. 6). 
Sequential serum samples demonstrated an increase in specific antibody titre during the course of the 
infection. Vaccination with COPV VLPs or an autogenous wart homogenate was not associated with 
any clinical response, despite the presence of high antibody titres. The IgG antibody titres were greater 
than those from normal control dogs (mean titre of six normal beagles prior to infection with COPV). 
 
Discussion 
Various efforts have been made to demonstrate the influence of the immune system on the outcome of 
papillomavirus infection. Early studies failed to demonstrate increased persistence of papillomas in 
rabbits immunosuppressed using cortisone (Evans et al., 1962). There are, however, occasional reports 
of severe or generalised papillomatosis in dogs immunosuppressed by prednisolone (Sundberg et al., 
1994; Nagata et al., 1995; Le Net et al., 1997). Oral papillomatosis has been seen also in a dog with 
hypogammaglobulinaemia (Bredal, 1996) and another report described multiple cutaneous squamous 
papillomas associated with IgM deficiency and impaired T-cell responses (Mill and Campbell, 1992). 
Studies in cattle support the hypothesis that immunosuppression after bracken feeding (Campo et al., 
1992; 1994) or azathioprine treatment (Campo et al., 1992) worsens papillomavirus-associated disease, 
with lesions becoming extensive, extending down the oesophagus to the rumen without regression. The 
extension of non-regressing papillomas along the oesophagus in immunosuppressed cattle may be 
analagous to the findings in the dog reported here. Similar associations are documented in people  
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immunosuppressed by human immunodeficiency virus infection or iatrogenic means (Stark et al., 1994; 
Benton and Arends, 1996). Occasionally, persistent and generalised human papillomavirus infections, 
refractory to treatment, have been associated with primary immunodeficiency (Gaspari et al., 1997). 
 
The unusual natural COPV infection reported here provided an opportunity to investigate some aspects 
of non-regressing papillomatosis. The differential white cell count provided no haematological evidence 
of immunosuppression. The dog did not have signs of unusual or severe bacterial, protozoal or fungal 
infections, as might be expected in cell-mediated immunodeficiency. Serum protein electrophoresis 
demonstrated raised gamma globulin levels, probably due to increased immunoglobulins associated 
with an active B-cell immune response. ELISA demonstrated the presence of high titres of anti-COPV 
IgG. These findings indicate that successive crops of warts were able to occur despite the presence of 
neutralising antibody. Although the dog already had severe papillomatosis at first presentation, it is 
possible that the first episode of electrocautery may have allowed the virus to establish latency in 
numerous keratinocytes within the traumatised and regenerating epithelium. Latency has been 
demonstrated in other animal papillomavirus infections (Amtmann et al., 1984; Campo et al., 1994) and 
seems also to occur in RRP. Once latent infection was established, the presence of neutralising antibody 
would have been unable to prevent development of lesions from the infected keratinocytes. The 
numerous episodes of epithelial trauma, associated with five electrocautery sessions, may have caused 
reactivation of latent infections by the stimulation of epithelial proliferation and healing. Surgical 
interference has been documented as exacerbating papillomatosis in the dog (Collier and Collins, 
1994). Although no published data address the issue of breed-related variations in response to 
papillomavirus infection, the authors (including a veterinary pathologist and a veterinary clinician) have 
seen multiple biopsies and clinical cases of uncomplicated wart regression in labrador dogs 
(unpublished observations) and are unaware of any such breed variations. These observations and the 
absence of significant lymphocyte infiltration in the clinical biopsies suggest that defective cellular 
immunity allowed warts to persist. Infection by a more pathogenic variant of COPV would be an 
alternative explanation. Sequence variants with differing pathogenicity have been described for some 
HPVs (Xi et al., 1997) and in the rabbit (Salmon et al., 1997). Infection with a more pathogenic variant 
of COPV was shown by sequencing and experimental infections not to be the cause of the unrestricted 
viral replication described in the present case.  
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 The ELISA data from this unfortunate dog show that vaccination with VLPs, and increased antibody 
titres to the wild-type viral particle, failed to alter the course of an established infection, despite the 
titres being greater than those which would normally prevent re-infection. The development of high 
anti-capsid antibody titres is clearly ineffective in the removal of established papilloma infections, and 
design of immunotherapeutic strategies will need to take this into account. 
 
The findings presented here document a new tropism for COPV, with viral infection not confined to the 
oral mucosa but extending throughout the oesophagus and also involving peri-oral haired skin and 
remote cutaneous sites. Additionally, these data show clearly that development of humoral immunity 
can neither clear established papillomavirus infections nor, under certain circumstances, prevent 
recurrent infections. Furthermore, these findings demonstrate that a virus normally causing insignificant 
spontaneously regressing papillomas can cause debilitating disease in some individuals. The most likely 
explanation of the phenomena in this animal is that host immunity was compromised. However, if this 
explanation is correct, the immune defect could be subtle, since the dog exhibited no other obvious 
signs of immune deficiency in either its haematological values or in its susceptibility to other 
opportunist pathogens. 
 
These findings support the hypothesis that the recurrent lesions seen in some human papillomavirus 
infections, such as RRP, are associated with specific defects in host immunity rather than variations in 
viral pathogenicity. Additionally, persistent papillomavirus infections in some individuals are unlikely 
to be responsive to therapeutic vaccination, highlighting the need for a greater understanding of the 
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Treatment/ Clinical Observations            Dates               
First presented for oral papillomatosis          1 Dec 1997   
Surgical removal of oral papillomas  , with electrocautery      4 Dec 1997, 22 Jan, 10 Apr, 30 Apr, and 3 Jun 1998 
First recurrence of lesions             22 Dec 1997 
Papillomas crushed with haemostats          29 Jan, 5 Feb, and 2 Apr 1998 
Papillomas plucked with haemostats          11 Feb, 25 Mar, and 2 Apr 1998 
Oral alpha-interferon (300 iu), once a day           11-17 and 24-30 Feb 1998 
Oral levamisole (75 mg), every other day          2 Apr – 10 May, and 30 Jun-30 Aug 1998 
Intravenous immunoregulin (1.5 cc)          10, 15, 18, 22, 30 Apr, and 3 Jun 1998 
Oral enrofloxacin (100 mg) once a day          10 Apr – 5 May, and 3-10 Jun 1998  
Intravenous vincristine (0.6mg)            8, 16, 22 May (all 0.6 mg), and 29 May 1998 (0.75 mg) 
COPV L1 VLP vaccine (20 µg) with aluminium hydroxide, subcutaneously  6 Jun 1998 
Booster COPV L1 VLP vaccine, without adjuvant, subcutaneously    12, 19, 25 Jun, and 2 Jul 1998 
First dose of autogenous wart homogenate vaccine (1 cc), subcutaneously  2 Jul 1998 
Booster autogenous wart homogenate vaccine, subcutaneously     9 (1 cc), 15 (1.5 cc), 22 (2 cc), and 29 (3 cc) July 1998 
Euthanasia due to persistent papillomatosis of oral cavity, including larynx and 
peri-oral haired skin, and other cutaneous sites        6 Aug 1998 Table 2. PCR amplification and sequencing of purified COPV DNA isolated from a case of non-regressing papillomatosis  
 
 
Primers              Predicted product     Size by electrophoresis       
Partial ORF series 
COPV E1  P1: caatcgaattctgaggggcaaagacaggtag   330 bp including nt1199 to 1506  300-394 bp  (confirmed by sequencing) 
  P2: taataggatccgcacaaacaaacataataat  
COPV E1b  P1: atcgtaggatccaaatatcttcgcagcagatg  243 bp including nt2391 to 2609  Close to 234 bp  (confirmed by sequencing) 
   P2: atcgtagaattctcatacagactcagtagttcc 
COPV E2   P1: caacagaattcaagggcataatgaggatagg  385 bp, including nt2694 to 3058  Close to 394 bp  (confirmed by sequencing) 
   P2: attcgggatccataatacacctgctgagtcc 
COPV E2b  P1: agctggggatcctaatagttt      259 bp including nt3460 to 3710  234-298 bp  (confirmed by sequencing) 
P2: atcgtagaattcttataactcatctaaccctcc 
COPV E4   P1: cacttgaattccggtgcctgttcccttaccc   257 bp including nt3193 to 3429  234-298 bp  (confirmed by sequencing) 
   P2: atcttggatcccagaagtcttcccagtcgtc 
COPV E6   P1: caacggaattcgatctttgcatgtctctaaa    363 bp including nt150 to 492  298-394 bp  (confirmed by sequencing) 
   P2: atctcggatccctgaccacagaaaaatcgtt  
COPV E7   P1: caactgaattcgagcagccggagccgataga   187 bp including nt575 to 740  154-234 bp  (confirmed by sequencing) 
   P2: attcgggatccatcctctttttgagacagac  
COPV L1   P1: catccgaattcatgtccaccaatagaactga  381 bp including nt7397 to 7755  Close to 394 bp  (confirmed by sequencing) 
   P2: caactggatccgtccctcactagaaaccaga 
COPV L2   P1: caacggaattcaagattaccactgatgctca  362 bp including nt5771 to 6110  298-394 bp  (confirmed by sequencing) 
   P2: atcttggatccgctgatatcttcgcctatta 
Full ORF series  
COPV E1  P1: atcgtaggatccatggcggctagaaaaggtact  1818 bp including nt816 to 2608  1.6-2.0 kb  (not sequenced) 
P2: atcgtagaattctcatacagactcagtagttcc 
COPV E2   P1: atcgtaggatccatggagaaactcagcgaggcc  1182 bp including nt2551 to 3708  1.0-1.6 kb  (not sequenced) 
P2: atcgtagaattcttataactcatctaaccctcc 
COPV E7  P1: atcgtaggatccatgattgggcaatgcgcaac  318 bp including nt533 to 826  Close to 344 bp  (not sequenced) 
P2: atcgtagaattcctagccgccatggtcaagct 






FIG.  1.  Nonregressing  canine   oral  papillomatosis.  Multiple  crops   of  papillomas   affect  the  buccal   mucosa,  tongue,  and  
palatine   mucosa  (a), extending  onto  the  perioral  haired  skin  (b). Papillomas  of the  buccal  mucosa (c) and tongue  (d) show 















FIG.  2.  Confirmation  of diagnosis. Histological  examination   of haematoxylin  and  eosin-stained sections  (a  and  b)  reveals  
superficial  vacuolated  (koilocytic)  keratinocytes  typical  of productive  papillomavirus  infections.  Immunohistochemistry    reveals  
abundant viral capsid   antigen  (L1)  in the  cells  of the  stratum  granulosum   (c). In situ  hybridisation  for COPV  genomic  DNA 
confirms  the  presence of abundant viral DNA in affected  epithelial  cells  (f). Normal  canine  buccal  mucosa (d) is  included  for 















FIG. 3. Electron  microscopy  of canine  oral papillomas.  Abundant  virions, both free and  in close-packed crystalline  arrays, 
are  seen  in the  nucleus  of  superficial  keratinocytes   within  the  papillomas.  The nuclear   envelope   is  seen   crossing   toward  












FIG.  4.  Postmortem   findings.  At postmortem   examination,  papillomas   were  found  to  be  widespread  within the  oral  
cavity, including  the  area  immediately  surrounding  the  larynx (a). Additionally, papillomas  were  found extending along  the 

















FIG. 5. Identification of viral DNA and  capsid  antigen  in oesophageal lesions.  Viral DNA was  abundant within oesophageal 
papillomas  (a and  c), as  detected by in situ hybridisation.  Adjacent unaffected  epithelium  is free of detectable viral DNA, giving a 
sharp  demarcation  between  negative  (left)  and  positive  (right)  mucosa  (c).  Viral  capsid  (L1)  antigen,  detected  by 
immunohistochemistry, was  present in scattered superficial  keratinocytes of the stratum granulosum  and  stratum  corneum  (b and 








FIG. 6. Parallel ELISA titration of serum  samples from a  dog  with nonregressing COPV lesions.  Sera  were  taken before  and 
during the  period  of vaccination  with COPV L1 VLPs and  autogenous wart homogenate. A rise  in titer is seen during the  course  
of the  infection, but  this  failed to cause resolution  of the  lesions.  The  control  data  represent mean  titres  from six uninfected  
beagles. 
 
 
 
 
 
 
 
 
 
 
 